Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YWHAZ | P63104 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | PLCG2 | P16885 | 2/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 3/20 | 0.31 |
| ▸ | AKT2 | P31751 | 2/20 | 0.31 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198145 | 1.00 | YWHAZ (0.32) | YWHAZTLR4PLCG2GBA1AKT1 | |
| SCHEMBL4199815 | 0.86 | TLR4 (0.38) | TLR4 | |
| SCHEMBL4197555 | 0.85 | YWHAZ (0.32) | YWHAZTLR4 | |
| SCHEMBL4196416 | 0.85 | YWHAZ (0.32) | YWHAZTLR4 | |
| SCHEMBL4191936 | 0.85 | YWHAZ (0.32) | YWHAZTLR4 | |
| SCHEMBL4199953 | 0.85 | TLR4 (0.34) | TLR4 | |
| SCHEMBL4207485 | 0.81 | TLR4 (0.39) | TLR4 | |
| SCHEMBL4197240 | 0.80 | CA1 (0.47) | — | |
| SCHEMBL28066867 | 0.78 | GBA1 (0.41) | GBA1 | |
| SCHEMBL28066822 | 0.78 | GBA1 (0.41) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1702926-A1 | LEVULOSE GLUCOSELIPID A ANALOGUE | Sankyo Company, Limited (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SLC2A3, GPR119, SLC2A2 | YWHAZ 1083/4885TLR4 294/4885PLCG2 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.